MHRA Strategy 2030 Signals a New Direction for Medical Device Regulation

Regulatory Update | Medical Devices & MedTech | October 2026

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has set out its regulatory direction for the next five years, with a clear focus on modernising healthcare regulation while supporting innovation and faster access to new technologies.

Published on 14 October 2026, the MHRA Strategy 2030 outlines how the regulator plans to respond to rapid advances in science, technology, and global healthcare.

For medical-device manufacturers, MedTech companies, and businesses planning to enter the UK market, it offers a valuable preview of how the regulatory environment is expected to evolve through 2030 with particular emphasis on patient-centred regulation, faster and more predictable services, data-driven safety monitoring, AI, international collaboration, and MedTech innovation.

A New Regulatory Direction

The MHRA describes Strategy 2030 as a move toward a more modern model of regulation combining scientific rigour with greater use of digital technology and data, while improving the experience of patients, healthcare professionals, and innovators.

A central objective is making regulatory decision-making more open, transparent, and inclusive, while improving the speed and predictability of services.

For industry: modernisation isn't just about the rules. It also covers how companies interact with the regulator, and how decisions are made and communicated.

Medical Devices and Innovation

The MHRA identifies medical technology as a key part of the UK's future healthcare and life-sciences ecosystem. Under the strategy, it plans to provide clearer pathways, earlier engagement, and faster routes to patient access for emerging technologies, helping innovations move more efficiently from approval into clinical pathways, adoption, and scale.

What this means: for innovative devices, early regulatory engagement becomes increasingly valuable. Rather than waiting until a product is ready for submission, companies may benefit from considering regulatory pathway and evidence strategy much earlier in development.

AI and Digital Health Take Centre Stage

AI is one of the most prominent themes in the strategy. The MHRA recognises that AI and digital technologies are transforming medical technology and that regulation must evolve alongside them.

Key planned initiatives:

• A modern, adaptive regulatory framework for AI as a medical device, supporting safe, effective, and equitable adoption while maintaining public confidence

• A new MHRA Centre for AI and Digital Health, providing clearer regulatory expectations for developers of digital and AI-driven devices and medicines.

  
  

This direction is especially relevant for manufacturers whose products incorporate machine learning, clinical decision support, automated analysis, or other AI-enabled features.

AI Airlock Enters Its Next Phase

The strategy follows another important development. On 6 October 2026, the MHRA opened applications for Phase 3 of the AI Airlock, its regulatory sandbox for AI-enabled medical devices.

Phase 3 focuses on regulatory challenges around post-market surveillance and lifecycle oversight of AI-enabled devices, with applications open on an ongoing basis.

The AI Airlock lets the MHRA work directly with innovators to identify and address regulatory challenges, and the insights gained are intended to inform a framework that stays fit for purpose as AI evolves. For companies developing AI-enabled devices, it's another opportunity to engage with the UK's evolving approach.

A Stronger Focus on Data-Driven Safety

The strategy also signals a shift toward continuous, real-time safety assurance using data, analytics, and AI to identify safety risks earlier and respond faster, across the full lifecycle of medicines and medical devices.

For manufacturers: market authorisation is not the end of the regulatory journey. You'll need systems to monitor device performance, identify emerging risks, and respond when new safety information emerges, and these systems should be considered from the start of product development.

International Recognition and Market Access

The MHRA also plans to strengthen international collaboration by:

• Expanding reliance and recognition routes with trusted regulators, including continued recognition of CE-marked devices

• Working with international regulators through Regulatory Innovation Corridors to reduce duplication and speed progress toward clinical studies

  
  

For international manufacturers, greater regulatory cooperation could reduce duplicated work and simplify multi-market navigation.

Keep in mind: assess each market's specific requirements. Recognition in one jurisdiction doesn't automatically provide access to another.

What Does This Mean for Manufacturers?

Strategy 2030 doesn't require companies to immediately change existing registrations. Instead, it provides a direction of travel useful for long-term regulatory planning. Expect continued development in:

• Medical-device regulation

• AI-enabled medical devices

• Digital health

• Regulatory science

• Post-market surveillance

• Data-driven safety monitoring

• International reliance and recognition

• Regulatory engagement and innovation

  
  

What Companies Should Do Now

1. Monitor UK regulatory reform. Follow MHRA developments as it works toward its 2030 goals. The UK government is also developing reforms to the legislative framework for medicines and medical devices, including measures to make legislation easier to update and to support a future medical-device licensing regime.

2. Assess AI-enabled products. Consider how the evolving UK framework may affect your regulatory strategy, including intended purpose, classification, clinical evidence, performance, risk management, and post-market monitoring.

3. Engage early. The MHRA's emphasis on early engagement suggests companies developing innovative technologies should plan regulatory interaction earlier in the product lifecycle.

4. Strengthen lifecycle management: Integrate post-market surveillance and safety monitoring into your overall regulatory strategy. As the MHRA leans on data and AI for safety monitoring, expect higher expectations for how manufacturers collect, analyse, and respond to post-market information.

5. Review international market strategies: Track UK recognition and reliance pathways, and consider how they interact with your regulatory strategies for Europe and other major markets.

ARQon Insight

MHRA Strategy 2030 is more than an organisational plan for medical-device companies, it's a roadmap for where UK regulation is heading.

The emphasis on AI, digital health, data-driven safety, international collaboration, and faster access to innovation suggests manufacturers will increasingly need to think beyond traditional pre-market registration. Regulatory strategy for the UK will need to cover the entire product lifecycle:

Product Development → Regulatory Strategy → Clinical Evidence → Market Access → Post-Market Surveillance → Ongoing Compliance

Our take: the companies best positioned won't be the ones reacting after changes become mandatory. They'll be the ones who monitor regulatory direction early and build it into their market-access planning.

Looking Toward 2030

The MHRA's stated ambition is to become a faster, expert, and open regulator by 2030 while keeping patient safety at the centre. The strategy aims to position the UK as a strong environment for developing and adopting innovative healthcare technologies, while ensuring they remain safe and effective.

For manufacturers and innovators, this brings both opportunity and responsibility: faster access to innovation must be balanced with robust evidence, effective safety monitoring, and appropriate oversight a balance that AI and digital health will make increasingly important.

Key Takeaway

The UK's MHRA Strategy 2030, published on 14 October 2026, sets a clear direction toward more modern, data-driven, and innovation-focused healthcare regulation with particular emphasis on AI and digital health, earlier engagement, lifecycle safety monitoring, international collaboration, and more predictable routes to market.

It doesn't immediately replace existing medical-device requirements, but it offers valuable insight into the environment companies can expect over the coming years.

For manufacturers entering the UK market, understanding where regulation is going can be just as important as understanding where it is today.

How ARQon Can Support You

ARQon supports healthcare and life-science companies with regulatory intelligence and market-access strategy across international markets, including:

• Regulatory intelligence and monitoring

• Medical-device market-entry strategy

• Regulatory pathway assessment

• Registration and documentation support

• Regulatory gap analysis

• Clinical and technical documentation planning

• Post-market regulatory strategy

• Cross-border market-access planning

  
  

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.

Sources

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom:

• MHRA Strategy 2030, published 14 October 2026

• MHRA AI Airlock Phase 3, published 6 October 2026